Obesity Treatment
SureNano Science Accelerates Development of Obesity Drug GEP-44, Initiates FDA-Aligned Preclinical Studies
SureNano Science has begun GLP toxicology and pharmacology studies for its lead drug candidate GEP-44, targeting obesity and type 2 diabetes, marking a crucial step toward clinical trials and FDA approval.
SureNano Science Targets Obesity Market with Novel GLP-1 Therapy GEP-44
SureNano Science Ltd. is advancing a differentiated GLP-1-based therapy, GEP-44, aiming to compete in the rapidly growing obesity and metabolic disease market dominated by blockbusters like Ozempic and Wegovy.
SureNano Science's GEP-44 Could Disrupt the Obesity Drug Market with Improved Tolerability
SureNano Science Ltd. is advancing GEP-44, a next-generation GLP-1 therapy with a triple agonist mechanism, aiming to improve upon current obesity treatments by offering better tolerability and potential non-injectable delivery.
SureNano Science Featured in BioMedWire Editorial Highlighting GLP-1 Innovation
SureNano Science Ltd. was featured in a BioMedWire editorial discussing its subsidiary GlucaPharm Inc. and its GEP-44 triple agonist peptide, which aims to improve obesity and diabetes treatment with better tolerability and potential non-injectable delivery.
SureNano Science Featured in BioMedWire Editorial on Next-Generation GLP-1 Innovation
SureNano Science Ltd. and its subsidiary GlucaPharm Inc. are highlighted for developing GEP-44, a novel triple agonist peptide targeting the expanding GLP-1 market for obesity and metabolic disorders.
Next-Generation GLP-1 Innovation Could Unlock Massive Metabolic Healthcare Market Opportunities
The rising prevalence of obesity and type 2 diabetes is driving significant interest in next-generation GLP-1 therapies, with companies like SureNano Science Ltd. developing novel triple agonists that could improve efficacy and tolerability in a rapidly expanding market.
SureNano Science Aims to Overcome GLP-1 Therapy Limitations with Triple Agonist Peptide
SureNano Science Ltd. is developing GEP-44, a triple agonist peptide targeting GLP-1 and PYY receptors, to address efficacy, tolerability, and delivery challenges in the rapidly expanding obesity and metabolic disease market.
SureNano Science’s GLP-1 Triple Agonist GEP-44 Targets Obesity Market as Next-Generation Therapies Gain Traction
SureNano Science Ltd. is highlighted in a BioMedWire editorial for its subsidiary GlucaPharm’s GEP-44 triple agonist peptide, which aims to improve efficacy, tolerability, and delivery flexibility in the growing GLP-1 market for obesity and metabolic diseases.
SureNano Science Advances GEP-44 as Obesity Drug Market Poised to Exceed $200 Billion
SureNano Science Ltd., through its subsidiary GlucaPharm Inc., is developing GEP-44, a next-generation GLP-1 triple agonist peptide targeting obesity and metabolic disorders, as the global market for such therapies is projected to surpass $200 billion.
SureNano Science Advances Next-Generation GLP-1 Platform with Triple Agonist Peptide GEP-44
SureNano Science Ltd. is developing GEP-44, a novel triple agonist peptide for improved GLP-1 therapy, aiming to address obesity and diabetes alongside major players like Eli Lilly and Novo Nordisk.
SureNano Science Advances GLP-1 Drug Candidate Toward Clinical Trials, Expands Investor Outreach
SureNano Science Ltd. is moving its lead obesity and diabetes drug GEP-44 into FDA IND-enabling studies with LabCorp while broadening investor communications through a partnership with Investor Brand Network.